Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy
Authors:
Open Access
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 18 (11) , 2582-2591.e6
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- National Major Science and Technology Projects of China
This publication has 26 references indexed in Scilit:
- Nonalcoholic Steatohepatitis Is Associated With Liver‐Related Outcomes and All‐Cause Mortality in Chronic Hepatitis BHepatology, 2019
- Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patientsJournal of Hepatology, 2018
- On‐treatment changes of liver stiffness at week 26 could predict 2‐year clinical outcomes in HBV‐related compensated cirrhosisLiver International, 2017
- Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort StudyGastroenterology, 2017
- New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatmentHepatology, 2016
- Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinationsAlimentary Pharmacology & Therapeutics, 2014
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡Hepatology, 2010
- Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA LevelJAMA, 2006
- Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver DiseaseNew England Journal of Medicine, 2004